Clinical features and outcomes of patients with acute myeloid leukemia: the single-center experience of 668 patients in China-Reference-Cited by-同舟云学术

Clinical features and outcomes of patients with acute myeloid leukemia: the single-center experience of 668 patients in China

Published:2024-02-07 Issue:1 Volume:29 Page:
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Ding Jie¹,Su Yang²,Ruan Yinglu³,Li Nan⁴,Meng Qianchao⁵,Yang Jiabang⁶,Chen Li⁶,Liu Chi⁴

Affiliation:

1. Department of Hematology, Jing’an District Centre Hospital of Shanghai, Fudan University, Shanghai, People’s Republic of China

2. Department of Hematology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China

3. Department of Rehabilitation Medicine, Jing’an District Center Hospital of Shanghai, Fudan University, Shanghai, People’s Republic of China,

4. Department of Geriatrics Center & National Clinical Research Center for Aging and Medicine, Jing’an District Centre Hospital of Shanghai, Fudan University, Shanghai, People’s Republic of China

5. Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China

6. Department of Hematology, Changhai Hospital, Naval Military Medical University, Shanghai, People’s Republic of China

Funder

Health Research project of Jing’an District, Shanghai

National Key R&D Program of China

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2024.2310960

Reference24 articles.

1. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy

2. Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome

3. Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201

4. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

5. Enhancing cytotoxicity of daunorubicin on drug-resistant leukaemia cells with microparticle-mediated drug delivery system